# Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients

> **NCT04427098** · PHASE2 · COMPLETED · sponsor: **IRCCS Azienda Ospedaliero-Universitaria di Bologna** · enrollment: 301 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Enoxaparin 40 Mg/0.4 mL Injectable Solution
- **DRUG:** Enoxaparin

## Key facts

- **NCT ID:** NCT04427098
- **Lead sponsor:** IRCCS Azienda Ospedaliero-Universitaria di Bologna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-22
- **Primary completion:** 2021-09-29
- **Final completion:** 2021-09-29
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04427098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04427098, "Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04427098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*